Fluoride

Fluoride

SCHEMBL21629484

F.F.[NaH].[NaH].[NaH]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL29203898 1.00
Fluoride SCHEMBL5706468 1.00
Fluoride SCHEMBL4246866 1.00
Fluoride SCHEMBL35954 1.00
Fluoride SCHEMBL21629483 1.00
Fluoride SCHEMBL9116839 1.00
Fluoride SCHEMBL372355 1.00
Fluoride SCHEMBL16694049 1.00
Fluoride SCHEMBL9244503 1.00
Fluoride SCHEMBL28698758 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3826619-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE Bayer Aktiengesellschaft (DE) 2021-06-02 EP disclosed
EP-3826627-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE Bayer Aktiengesellschaft (DE) 2021-06-02 EP disclosed
WO-2020020789-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE BAYER AKTIENGESELLSCHAFT (DE) 2020-01-30 WO disclosed
WO-2020020790-A1 PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE BAYER AKTIENGESELLSCHAFT (DE) 2020-01-30 WO disclosed